Dalcetrapib increased HDL-C and ApoA1 to a similar extent in patients with low HDL-C resulting from mutations (i.e., familial hypoalphalipoproteinemia; FHA) and patients with low HDL-C not arising from mutations (i.e., familial combined hyperlipidemia); however, patients with FHA did not have an increase in plasma campesterol. Here, APOA1 is linked to hypoalphalipoproteinemia, primary, 1.